KGX Kodagenix
KGX / Understand the evidence

GLP-1 &
supplements.

What the research says about berberine, fiber and the difference between a supplement and a medicine.

A familiar ingredient name does not tell you whether a product has been shown to affect GLP-1. The specific formula, dose and human research matter.

What is GLP-1?

GLP-1 stands for glucagon-like peptide-1. It is a hormone involved in appetite and food-intake regulation. Prescription GLP-1 receptor agonists, including semaglutide and liraglutide, mimic its activity. Tirzepatide acts on both the GIP and GLP-1 pathways. A supplement containing plant compounds or fiber is not the same intervention. NIDDK explains these medicines ↗

Keep the comparison clear.

Research on a hormone measurement does not, by itself, show that a supplement delivers the effects of a prescription medicine.

Does berberine work like a GLP-1 medicine?

Berberine is a plant-derived compound. It should not be treated as equivalent to a GLP-1 medicine. The U.S. National Center for Complementary and Integrative Health describes the evidence for berberine and weight loss as inconclusive, with inconsistent results and limitations in study quality. Read NCCIH’s overview ↗

Human GLP-1 findings need context. A 16-week trial using 1,000 mg of berberine daily reported similar changes in GLP-1 across its treatment groups, despite improvements in some glucose measures. Ming and colleagues, 2021 ↗

A smaller 2026 crossover study reported increased GLP-1 with a particular bio-optimized berberine formulation. It involved 36 adults and 14-day treatment periods, and included authors affiliated with its developer. That short study does not establish long-term weight-loss results or equivalent effects from other berberine products. Jeyakodi and colleagues, 2026 ↗

Can inulin or other fibers increase GLP-1?

Some human studies explore this, but the results depend on the fiber, dose and study design. A small trial comparing 10 g and 16 g of oligofructose daily with placebo found a higher GLP-1 response at 16 g than at 10 g. A separate acute study using 24 g of inulin did not increase GLP-1 responses. These are different experiments, not proof that any fiber-containing capsule will produce a GLP-1 benefit. Oligofructose trial, 2011 ↗ Inulin trial, published 2017 ↗

The amounts above describe research, not recommended supplement doses.

Are Thermogenix and Thermogenix-PM GLP-1 products?

Thermogenix and Thermogenix-PM are dietary supplements, not GLP-1 medicines. Kodagenix does not claim that either finished formula increases GLP-1 or provides the same results as prescription treatment.

The 2025 Thermogenix-PM label lists 500 mg of inulin and 150 mg of berberine per capsule. Those ingredient names alone do not connect the finished formula to the results of the studies above. Formulation, daily amount and measured outcomes must all be considered.

Can I take supplements with a GLP-1 prescription?

Ask your prescriber or pharmacist to review the complete supplement label first. Berberine can cause digestive side effects and interact with medicines; it may also be unsafe during pregnancy or breastfeeding. Do not replace a prescribed medicine with a supplement. NCCIH safety information ↗

Four checks before trusting a claim.

  1. The actual formula. Was the finished product tested, or only one ingredient?
  2. The amount and form. Does the label match the study’s daily dose and ingredient preparation?
  3. The people and duration. Who participated, how many people were included and how long did the trial run?
  4. The result that matters. Was the finding a hormone measurement, a symptom, or a sustained health outcome?

Read our guide to interpreting ingredient research ↗

Read the sources.

These selected sources provide context, not a systematic review. This article is published by Kodagenix, a supplement brand, for general education and is not personalized medical advice.

  1. NIDDK: Prescription medications for overweight and obesity
  2. NCCIH: Berberine and weight loss
  3. Ming et al. (2021): Randomized berberine trial
  4. Jeyakodi et al. (2026): Formulation-specific crossover trial
  5. Verhoef et al. (2011): Oligofructose dose trial
  6. Rahat-Rozenbloom et al. (2017): Acute inulin trial

Sources checked October 29, 2026. Product-label questions: sales@kodagenix.com.